No annual revenue total was found in METAVIA INC.'s SEC filings.
Metavia Inc. (MTVA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$15.7 million. As of Jun 30, 2026 it held $12.6 million in cash and investments and $177,000 in total debt.
Revenue
—
Net income (TTM)
$-14.45M
+21.9% vs year-ago TTM
Operating cash flow (TTM)
$-15.84M
+16.2% vs year-ago TTM
Free cash flow
$-15.70M
+36.5% vs prior year
EPS (TTM)
$-3.74
-127.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
5.09M
-41.2% vs prior year
Net cash
$12.46M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MTVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1638287
- Former names
- NeuroBo Pharmaceuticals, Inc. (until Nov 18, 2024); Gemphire Therapeutics Inc. (until Dec 31, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$13.7M | -$28.8M | -$15.9M | -$19.6M | -$15.3M |
| Net income | -$13.0M | -$27.6M | -$12.5M | -$14.0M | -$15.3M |
| Diluted EPS | -$7.35 | -$39.13 | -$2.46 | -$43.42 | -$19.81 |
| Operating cash flow | -$15.7M | -$24.7M | -$10.8M | -$11.7M | -$15.1M |
| Free cash flow | -$15.7M | -$24.7M | -$10.8M | — | -$15.1M |
| Total assets | $11.1M | $16.3M | $22.8M | $33.5M | $16.8M |
| Total liabilities | $5.8M | $8.3M | $6.1M | $11.8M | $2.2M |
| Stockholders' equity | $5.3M | $7.9M | $16.7M | $21.8M | $14.6M |
| Cash and investments | $10.3M | $16.0M | $22.4M | $33.4M | $16.4M |
| Total debt | $210,000 | $136,000 | $203,000 | — | $71,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
All 633 Metavia Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.